Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia

Starting soon

Conditions studied: Thrombocytopenia, Platelet Transfusion, Haemorrhage, Hematologic Malignancies

In brief

The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an association study, and to establish a threshold that enables the prediction of the immediate risk of bleeding in haematology patients with severe thrombocytopenia (\<20 G/L); with a view to selecting a population with a residual risk of bleeding of zero (NPV ≥ 95%, to achieve a residual probability of bleeding \< 5%). The score may incorporate variables identified in the literature as having a plausible causal relationship with the occurrence of bleeding (14,15), as well as viscoelastometric tests parameters, conventional haemostasis parameters and relevant clinical parameters. . Participants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 21.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, urea, creatinin, albumin.

Key facts

Study ID

NCT07653672

Run by

Centre Hospitalier Annecy Genevois

People needed

410

Starts

2026-06-30

Expected to finish

2028-07-15

Last updated by the study team

2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients;
• Who have been informed about the study and have freely given their informed consent to participate in the study;
• With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment;
• With central thrombocytopenia strictly below 20 G/L in a blood sample taken less than 72 hours ago and not having received a transfusion since;
• Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic;
• With or without active bleeding;
• Affiliated with or covered by a social security scheme.

You may not qualify if…

• Patients who have received at least one of the following treatments:
• Antiplatelet agents within 7 days prior to enrolment,
• Vitamin K antagonists within 7 days prior to enrolment,
• Direct oral anticoagulants within 72 hours prior to enrolment,
• Low molecular weight heparin within 24 hours prior to inclusion,
• Unfractionated heparin within 6 hours prior to inclusion,
• Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion;
• Patients with a history of thrombopathy;
• Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis;
• Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation;
• Patients already enrolled in the study;
• Pregnant or breastfeeding women;
• Patients under guardianship or curatorship;
• Patients who do not understand French;
• Patients under judicial protection.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.